A
19.98
-0.20 (-0.99%)
| Penutupan Terdahulu | 20.18 |
| Buka | 19.92 |
| Jumlah Dagangan | 551,831 |
| Purata Dagangan (3B) | 1,050,404 |
| Modal Pasaran | 2,483,813,632 |
| Harga / Pendapatan (P/E Ke hadapan) | 111.11 |
| Harga / Jualan (P/S) | 656.60 |
| Harga / Buku (P/B) | 13.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 Nov 2024 - 2 Dec 2024 |
| Margin Operasi (TTM) | -2,785.05% |
| EPS Cair (TTM) | -5.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 133.97% |
| Nisbah Semasa (MRQ) | 4.65 |
| Aliran Tunai Operasi (OCF TTM) | -351.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -413.91 M |
| Pulangan Atas Aset (ROA TTM) | -40.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -151.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arrowhead Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.25 |
|
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.47% |
| % Dimiliki oleh Institusi | 79.71% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (HC Wainwright & Co., 300.40%) | Beli |
| Median | 43.50 (117.72%) | |
| Rendah | 24.00 (Bernstein, 20.12%) | Pegang |
| Purata | 46.17 (131.08%) | |
| Jumlah | 4 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 23.26 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Dec 2024 | 80.00 (300.40%) | Beli | 19.45 |
| 03 Dec 2024 | 80.00 (300.40%) | Beli | 26.07 | |
| Chardan Capital | 12 Dec 2024 | 60.00 (200.30%) | Beli | 22.14 |
| 27 Nov 2024 | 60.00 (200.30%) | Beli | 26.15 | |
| Bernstein | 29 Nov 2024 | 24.00 (20.12%) | Pegang | 26.03 |
| Citigroup | 27 Nov 2024 | 26.00 (30.13%) | Pegang | 26.15 |
| Piper Sandler | 27 Nov 2024 | 45.00 (125.23%) | Beli | 26.15 |
| 08 Oct 2024 | 62.00 (210.31%) | Beli | 18.02 | |
| RBC Capital | 26 Sep 2024 | 42.00 (110.21%) | Beli | 19.62 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |